General Information of Drug (ID: DMDRK68)

Drug Name
PMID29053063-Compound-11d Drug Info
Cross-matching ID
TTD Drug ID
DMDRK68

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [2]
Thiopental DMGP8AX Anaesthesia 9A78.6 Approved [3]
JNJ-42165279 DM72GZO Anxiety disorder 6B00-6B0Z Phase 2 [4]
SSR411298 DMGTB2Q Major depressive disorder 6A70.3 Phase 2 [5]
IW-6118 DMP42W1 Inflammation 1A00-CA43.1 Phase 2 [6]
PF-04457845 DMPRYU1 Liver disease DB90-BD99 Phase 2 [7]
IPI-940 DMEIM5G Pain MG30-MG3Z Phase 1 [8]
Piperazine carbamic compound 1 DMZSYU4 N. A. N. A. Patented [1]
Piperazine carbamic compound 2 DMMQ0ZO N. A. N. A. Patented [1]
Pyrazole derivative 82 DMETCI3 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoglyceride lipase (MAGL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABX-1431 DM9SYVJ Neuropathic pain 8E43.0 Phase 1 [9]
Piperazine carbamic compound 1 DMZSYU4 N. A. N. A. Patented [1]
Piperazine carbamic compound 2 DMMQ0ZO N. A. N. A. Patented [1]
Pyrazole derivative 82 DMETCI3 N. A. N. A. Patented [1]
Pyrazole derivative 81 DMWT437 N. A. N. A. Patented [1]
PMID29053063-Compound-15 DM07U5R N. A. N. A. Patented [1]
Pyrazole derivative 80 DMQ3TGM N. A. N. A. Patented [1]
Carbamide derivative 24 DMD6Y73 N. A. N. A. Patented [1]
Piperazine carbamic compound 4 DMKZUO4 N. A. N. A. Patented [1]
Carbamide derivative 26 DMDU9XF N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Piperazine carbamic compound 1 DMZSYU4 N. A. N. A. Patented [1]
Piperazine carbamic compound 2 DMMQ0ZO N. A. N. A. Patented [1]
Pyrazole derivative 82 DMETCI3 N. A. N. A. Patented [1]
Pyrazole derivative 81 DMWT437 N. A. N. A. Patented [1]
Pyrazole derivative 80 DMQ3TGM N. A. N. A. Patented [1]
Piperazine carbamic compound 4 DMKZUO4 N. A. N. A. Patented [1]
PMID29053063-Compound-11c DMLMHR5 N. A. N. A. Patented [1]
Piperazine carbamic compound 5 DMXH65Z N. A. N. A. Patented [1]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fatty acid amide hydrolase (FAAH) TTDP1UC NOUNIPROTAC Inhibitor [1]
Monoacylglycerol lipase ABHD6 (ABHD6) TTSINOV ABHD6_HUMAN Inhibitor [1]
Monoglyceride lipase (MAGL) TTZ963I MGLL_HUMAN Inhibitor [1]

References

1 A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
2 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
3 The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
7 Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)